RU2020121929A - Фармацевтические комбинации - Google Patents
Фармацевтические комбинации Download PDFInfo
- Publication number
- RU2020121929A RU2020121929A RU2020121929A RU2020121929A RU2020121929A RU 2020121929 A RU2020121929 A RU 2020121929A RU 2020121929 A RU2020121929 A RU 2020121929A RU 2020121929 A RU2020121929 A RU 2020121929A RU 2020121929 A RU2020121929 A RU 2020121929A
- Authority
- RU
- Russia
- Prior art keywords
- amide
- pharmaceutically acceptable
- acceptable salt
- dimethylethyl
- thiazol
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims 4
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 2
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 claims 2
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 2
- 108010069236 Goserelin Proteins 0.000 claims 2
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 229960001442 gonadorelin Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- 229960003690 goserelin acetate Drugs 0.000 claims 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical group C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305057 | 2014-01-15 | ||
| EP14305057.3 | 2014-01-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016133285A Division RU2016133285A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020121929A true RU2020121929A (ru) | 2020-07-13 |
Family
ID=50033443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020121929A RU2020121929A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
| RU2016133285A RU2016133285A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016133285A RU2016133285A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160331755A1 (enExample) |
| EP (1) | EP3094340A1 (enExample) |
| JP (2) | JP2017502989A (enExample) |
| KR (1) | KR20160101027A (enExample) |
| CN (2) | CN112535688A (enExample) |
| AU (2) | AU2015207723A1 (enExample) |
| BR (1) | BR112016012141A2 (enExample) |
| CA (1) | CA2936783A1 (enExample) |
| MX (1) | MX2016009226A (enExample) |
| RU (2) | RU2020121929A (enExample) |
| WO (1) | WO2015107461A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111757734A (zh) * | 2017-12-28 | 2020-10-09 | 星座制药公司 | 通过组合疗法的ezh2抑制剂的药代动力学增强 |
| CN115040523A (zh) * | 2021-03-09 | 2022-09-13 | 上海翰森生物医药科技有限公司 | Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途 |
| WO2023150267A1 (en) * | 2022-02-03 | 2023-08-10 | Maison Amori Oqvpo Llc | Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101019828A (zh) * | 2007-03-23 | 2007-08-22 | 济南帅华医药科技有限公司 | 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物 |
| EP2155753A1 (en) * | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2558463A1 (en) * | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2012009649A1 (en) * | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| CN103764144B (zh) * | 2011-08-31 | 2016-07-20 | 诺华股份有限公司 | Pi3k抑制剂与mek抑制剂的协同组合 |
| CA2867700A1 (en) * | 2012-03-23 | 2013-09-26 | Memorial Sloan-Kettering Cancer Center | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
-
2015
- 2015-01-13 MX MX2016009226A patent/MX2016009226A/es unknown
- 2015-01-13 CN CN202011428621.1A patent/CN112535688A/zh active Pending
- 2015-01-13 EP EP15701257.6A patent/EP3094340A1/en not_active Withdrawn
- 2015-01-13 KR KR1020167018718A patent/KR20160101027A/ko not_active Abandoned
- 2015-01-13 BR BR112016012141A patent/BR112016012141A2/pt not_active Application Discontinuation
- 2015-01-13 AU AU2015207723A patent/AU2015207723A1/en not_active Abandoned
- 2015-01-13 CA CA2936783A patent/CA2936783A1/en not_active Abandoned
- 2015-01-13 RU RU2020121929A patent/RU2020121929A/ru unknown
- 2015-01-13 RU RU2016133285A patent/RU2016133285A/ru unknown
- 2015-01-13 US US15/109,704 patent/US20160331755A1/en not_active Abandoned
- 2015-01-13 CN CN201580004798.XA patent/CN105916515A/zh active Pending
- 2015-01-13 JP JP2016546785A patent/JP2017502989A/ja not_active Withdrawn
- 2015-01-13 WO PCT/IB2015/050260 patent/WO2015107461A1/en not_active Ceased
-
2017
- 2017-07-11 US US15/646,494 patent/US10085996B2/en not_active Expired - Fee Related
- 2017-10-10 AU AU2017245302A patent/AU2017245302B2/en not_active Ceased
-
2019
- 2019-09-13 JP JP2019167076A patent/JP2020023497A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105916515A (zh) | 2016-08-31 |
| JP2020023497A (ja) | 2020-02-13 |
| EP3094340A1 (en) | 2016-11-23 |
| RU2016133285A (ru) | 2018-02-20 |
| CA2936783A1 (en) | 2015-07-23 |
| MX2016009226A (es) | 2016-10-05 |
| WO2015107461A1 (en) | 2015-07-23 |
| AU2017245302A1 (en) | 2017-11-02 |
| JP2017502989A (ja) | 2017-01-26 |
| US20160331755A1 (en) | 2016-11-17 |
| KR20160101027A (ko) | 2016-08-24 |
| RU2016133285A3 (enExample) | 2018-08-28 |
| CN112535688A (zh) | 2021-03-23 |
| US20170304311A1 (en) | 2017-10-26 |
| AU2017245302B2 (en) | 2019-04-04 |
| AU2015207723A1 (en) | 2016-06-09 |
| BR112016012141A2 (pt) | 2017-08-08 |
| US10085996B2 (en) | 2018-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| JP2016518337A5 (enExample) | ||
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| EA201892746A1 (ru) | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| JP2015155440A5 (enExample) | ||
| CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| EA201691402A1 (ru) | Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты | |
| PH12016500042A1 (en) | Stabilized pharmaceutical dosage forms comprising atrasentan | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| PH12018501237A1 (en) | Isoindole compounds | |
| JP2020529995A5 (enExample) | ||
| FI3661510T3 (fi) | Menetelmiä käyttäytymismuutosten hoitamiseksi | |
| RU2017111848A (ru) | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи | |
| MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2015512948A5 (enExample) |